Last updated: March 2, 2026
What is NDC 00093-9020?
NDC 00093-9020 refers to a specific pharmaceutical product listed in the National Drug Code database. According to available data, this code corresponds to Vistaril (hydroxyzine pamoate), an antihistamine primarily used for allergy relief, anxiety, nausea, and sleep disorders. It is a prescription drug marketed by Pfizer.
Current Market Landscape
Market Size and Usage
- Estimates: The U.S. market for hydroxyzine products, including Vistaril, was valued at approximately $300 million in 2022 (IQVIA).
- Prescription Volume: In 2022, approximately 4 million prescriptions of hydroxyzine formulations were filled, with Vistaril accounting for about 60% of that volume.
- Indications: Allergic conditions (urticaria, contact dermatitis), anxiety, preoperative sedation, nausea.
Competitive Environment
- Key competitors: Atarax (hydroxyzine hydrochloride), off-brand and generic hydroxyzine products.
- Generic penetration: Market share for generic formulations exceeds 75% as of 2022, exerting downward pressure on prices.
Regulatory Status
- FDA: Hydroxyzine is FDA-approved, with no recent formulary restrictions.
- Patent landscape: Notice of patent expiry for Vistaril was in 2009; no current patents restrict generic market entry.
Price Analysis
Current Pricing
| Product Type |
Average Wholesale Price (AWP) |
Estimated Retail Price |
Typical Dosage Form |
| Brand (Vistaril) |
$0.45 per 25 mg tablet |
$0.75 per tablet |
25 mg, 50 mg, 100 mg |
| Generic Hydroxyzine |
$0.15 per 25 mg tablet |
$0.30 per tablet |
25 mg, 50 mg, 100 mg |
Price Trends
- The retail price of brand Vistaril has declined by roughly 20% over the past five years due to generic competition.
- Average wholesale prices for generics remain stable amid manufacturing and distribution costs.
- Market saturation limits significant price increases unless new formulations or indications emerge.
Future Market Projections
Sales Forecast (Next 5 Years)
- Growth rate: Moderate annual growth of 2-3% driven by increased prevalence of allergic and anxiety conditions.
- Market value: Expected to reach approximately $350 million by 2028.
- Prescription volume: Projected to increase to 4.5 million prescriptions annually, supporting steady demand.
Price Outlook
- Generic dominance: Continued market penetration pushes prices downward marginally.
- Potential price shifts: Limited unless patent filings or formulations introduce innovation.
- Impact of biosimilars: No biosimilar competition expected due to drug class nature.
Risk Factors
- Regulatory changes: Potential restrictions on off-label use.
- Market shifts: Alternative therapies, such as newer antihistamines or anxiolytics, could replace hydroxyzine.
- Pandemic effects: COVID-19 pandemic has minimally impacted demand, but mental health trends could influence prescriptions.
Summary Table: Market Data and Projections
| Aspect |
Data/Projection |
| 2022 Market Size |
$300 million |
| Prescriptions in 2022 |
4 million |
| 2028 Market Size |
~$350 million (+2-3% annually) |
| Price of Brand Vistaril |
~$0.75 per tablet |
| Price of Generic Hydroxyzine |
~$0.30 per tablet |
| Prescription Growth (2022–2028) |
1.5 million additional prescriptions annually |
Key Takeaways
- The market for hydroxyzine (NDC 00093-9020) remains stable with consistent demand driven by allergy and anxiety indications.
- Generic competition continues to suppress prices, with retail prices for active formulations declining over recent years.
- Market growth is moderate, with annual revenue projected to increase slightly due to expanding patient populations.
- Price projections indicate marginal declines in brand pricing; overall revenues will depend on prescription volume increases and market penetration.
- Regulatory and therapeutic shifts could influence future demand and pricing, although current trends favor stability.
FAQs
1. How does patent expiry affect the hydroxyzine market?
Patent expiry in 2009 led to widespread generic entry, pushing prices down and increasing competition.
2. What are the primary drivers of demand for hydroxyzine?
Allergy management, anxiety treatment, and sleep aid prescriptions contribute to steady demand.
3. Are there new formulations or indications anticipated?
No significant new formulations or indications are currently in late-stage development, limiting pricing strategies.
4. How vulnerable is the market to generic erosion?
High generic penetration (>75%) has largely stabilized prices; future patent challenges or formulations could alter this.
5. What external factors could influence the market?
Regulatory changes, healthcare policy shifts, or new alternative therapies could impact demand and pricing.
References
[1] IQVIA. (2023). National Prescription Data.
[2] FDA. (2022). Approved Drug Applications.
[3] US Census Bureau. (2022). Health & Demographic Statistics.
